Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels |
| |
Authors: | Spagnuolo Vincenzo Gentilini Gianluca De Bona Anna Galli Laura Uberti-Foppa Caterina Soldarini Armando Dorigatti Fernanda Seminari Elena |
| |
Institution: | Infectious Disease Department, San Raffaele Scientific Institute and Università Vita-Salute San Raffaele Milan, Italy. vincenzo.spagnuolo@tiscali.it |
| |
Abstract: | Acute liver toxicity is a frequent adverse event that occurs during antiretroviral therapy and was observed in 6-30% of the patients on treatment, especially in presence of HCV coinfection (Cooper et al., 2002, Maida et al., 2006, Sulkowski et al., 2000). A correlation between HCV-associated liver-fibrosis severity and the risk of HAART associated hepatoxicity has been demonstrated (Aranzabal et al., 2005, Sulkowski et al., 2004). This high liver toxicity rate might be due to increased drug exposure in patients with liver disease (Veronese et al., 2000). It has been reported that patients with chronic hepatitis C show significantly reduced CPY3A4 and CYP2D6 activity in comparison with healthy volunteers (Becquemont et al., 2002). The aim of this study was to evaluate the liver function tests in HCV-co-infected patients treated with fos-amprenavir and ritonavir. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|